JPMorgan Chase & Co. Has $2.32 Million Position in Dyne Therapeutics, Inc. (NASDAQ:DYN)

JPMorgan Chase & Co. decreased its holdings in shares of Dyne Therapeutics, Inc. (NASDAQ:DYN) by 3.3% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 98,387 shares of the company’s stock after selling 3,363 shares during the period. JPMorgan Chase & Co.’s holdings in Dyne Therapeutics were worth $2,318,000 as of its most recent SEC filing.

A number of other large investors have also recently made changes to their positions in DYN. KLP Kapitalforvaltning AS bought a new position in shares of Dyne Therapeutics in the fourth quarter valued at approximately $257,000. Magnetar Financial LLC bought a new position in Dyne Therapeutics during the 4th quarter valued at $263,000. Teacher Retirement System of Texas boosted its holdings in Dyne Therapeutics by 21.4% during the 4th quarter. Teacher Retirement System of Texas now owns 16,385 shares of the company’s stock worth $386,000 after acquiring an additional 2,883 shares during the last quarter. Privium Fund Management B.V. boosted its holdings in Dyne Therapeutics by 35.6% during the 4th quarter. Privium Fund Management B.V. now owns 20,366 shares of the company’s stock worth $480,000 after acquiring an additional 5,350 shares during the last quarter. Finally, Intech Investment Management LLC grew its stake in shares of Dyne Therapeutics by 31.6% in the 4th quarter. Intech Investment Management LLC now owns 33,976 shares of the company’s stock worth $800,000 after acquiring an additional 8,162 shares in the last quarter. 96.68% of the stock is owned by institutional investors.

Dyne Therapeutics Stock Up 8.8 %

Shares of NASDAQ:DYN opened at $10.79 on Thursday. The company has a 50-day moving average price of $10.90 and a two-hundred day moving average price of $20.01. Dyne Therapeutics, Inc. has a twelve month low of $6.36 and a twelve month high of $47.45. The firm has a market capitalization of $1.23 billion, a PE ratio of -3.03 and a beta of 1.21.

Dyne Therapeutics (NASDAQ:DYN) last released its quarterly earnings data on Tuesday, March 4th. The company reported ($0.88) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.92) by $0.04. Analysts anticipate that Dyne Therapeutics, Inc. will post -3.44 earnings per share for the current fiscal year.

Insider Activity at Dyne Therapeutics

In related news, insider Oxana Beskrovnaya sold 2,598 shares of the company’s stock in a transaction that occurred on Tuesday, February 18th. The shares were sold at an average price of $13.95, for a total transaction of $36,242.10. Following the sale, the insider now owns 199,087 shares of the company’s stock, valued at approximately $2,777,263.65. This represents a 1.29 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. In the last three months, insiders have sold 6,237 shares of company stock worth $77,760. 20.77% of the stock is owned by company insiders.

Wall Street Analysts Forecast Growth

A number of research analysts recently weighed in on DYN shares. Scotiabank started coverage on shares of Dyne Therapeutics in a research report on Friday, March 7th. They set a “sector outperform” rating and a $50.00 price target on the stock. Piper Sandler dropped their target price on shares of Dyne Therapeutics from $53.00 to $48.00 and set an “overweight” rating on the stock in a research report on Friday, February 28th. BMO Capital Markets initiated coverage on Dyne Therapeutics in a report on Wednesday, March 12th. They issued an “outperform” rating and a $50.00 target price for the company. HC Wainwright reiterated a “buy” rating and set a $46.00 price target on shares of Dyne Therapeutics in a report on Monday, March 17th. Finally, JPMorgan Chase & Co. reduced their price objective on Dyne Therapeutics from $18.00 to $17.00 and set a “neutral” rating for the company in a research note on Friday, March 21st. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating, twelve have issued a buy rating and two have issued a strong buy rating to the company’s stock. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of $47.46.

Dyne Therapeutics Company Profile

Dyne Therapeutics, Inc, a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics.